PMID- 20865740 OWN - NLM STAT- MEDLINE DCOM- 20120824 LR - 20181201 IS - 1098-1063 (Electronic) IS - 1050-9631 (Linking) VI - 21 IP - 9 DP - 2011 Sep TI - Cholinergic hypofunction impairs memory acquisition possibly through hippocampal Arc and BDNF downregulation. PG - 999-1009 LID - 10.1002/hipo.20812 [doi] AB - Recent evidence suggests that activity-regulated cytoskeleton associated protein (Arc) and brain-derived neurotrophic factor (BDNF) are key players in the cellular mechanisms that trigger synaptic changes and memory consolidation. Cholinergic deafferentiation of hippocampus has been largely shown to induce memory impairments in different behavioral tasks. However, the mechanisms underlying cholinergic-induced memory formation remain unclear. The role of hippocampal cholinergic denervation on synaptic consolidation and further acquisition of spatial memory was hereby examined by analyzing Arc and BDNF in standard environment and after behavioral training in Morris water maze (MWM). In standard environment, a cholinergic hypofunction induced by the toxin (192) IgG-saporin led to significant decreases in Arc protein and mRNA as well as in BDNF. Lesioned rats subjected to MWM showed a worse acquisition performance that was reversed after galantamine treatment. Recovery of memory acquisition was accompanied by normalization of Arc and BDNF levels in hippocampus. Stimulation of muscarinic, but not nicotinic receptors, in hippocampal primary neurons caused a rapid induction of Arc production. These data suggest that cholinergic denervation of hippocampus leads to deficits in muscarinic-dependent induction of Arc and a subsequent impairment of spatial memory acquisition. CI - Copyright (c) 2010 Wiley-Liss, Inc. FAU - Gil-Bea, Francisco J AU - Gil-Bea FJ AD - Department of Neurobiology, Care Sciences and Society, Karolinska Institutet-Alzheimer's Disease Research Center, Karolinska Institutet, Stockholm, Sweden. Francisco.Gil-Bea@ki.se FAU - Solas, Maite AU - Solas M FAU - Mateos, Laura AU - Mateos L FAU - Winblad, Bengt AU - Winblad B FAU - Ramirez, Maria J AU - Ramirez MJ FAU - Cedazo-Minguez, Angel AU - Cedazo-Minguez A LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20100602 PL - United States TA - Hippocampus JT - Hippocampus JID - 9108167 RN - 0 (192 IgG-saporin) RN - 0 (Antibodies, Monoclonal) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Cholinesterase Inhibitors) RN - 0 (Cytoskeletal Proteins) RN - 0 (Immunotoxins) RN - 0 (Nerve Tissue Proteins) RN - 0 (RNA, Messenger) RN - 0 (Receptors, Muscarinic) RN - 0 (Receptors, Nicotinic) RN - 0 (Ribosome Inactivating Proteins, Type 1) RN - 0 (activity regulated cytoskeletal-associated protein) RN - 0D3Q044KCA (Galantamine) RN - EC 3.2.2.22 (Saporins) RN - N9YNS0M02X (Acetylcholine) SB - IM MH - Acetylcholine/metabolism MH - Animals MH - Antibodies, Monoclonal/pharmacology MH - Brain-Derived Neurotrophic Factor/*metabolism MH - Cholinergic Fibers/drug effects MH - Cholinesterase Inhibitors/pharmacology MH - Cytoskeletal Proteins/genetics/*metabolism MH - Female MH - Galantamine/pharmacology MH - Hippocampus/drug effects/*metabolism/surgery MH - Immunotoxins/pharmacology MH - Male MH - Maze Learning/*physiology MH - Memory/*physiology MH - Memory Disorders/metabolism MH - Nerve Tissue Proteins/genetics/*metabolism MH - RNA, Messenger/metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Rats, Wistar MH - Receptors, Muscarinic/*metabolism MH - Receptors, Nicotinic/metabolism MH - Ribosome Inactivating Proteins, Type 1/pharmacology MH - Saporins EDAT- 2010/09/25 06:00 MHDA- 2012/08/25 06:00 CRDT- 2010/09/25 06:00 PHST- 2010/03/23 00:00 [accepted] PHST- 2010/09/25 06:00 [entrez] PHST- 2010/09/25 06:00 [pubmed] PHST- 2012/08/25 06:00 [medline] AID - 10.1002/hipo.20812 [doi] PST - ppublish SO - Hippocampus. 2011 Sep;21(9):999-1009. doi: 10.1002/hipo.20812. Epub 2010 Jun 2.